Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Diversified Financials
Create a narrative
Paysign Community
NasdaqCM:PAYS Community
3
Narratives
written by author
0
Comments
on narratives written by author
31
Fair Values set
on narratives written by author
Community Investing Ideas
Paysign
Popular
Undervalued
Overvalued
Paysign
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Digital Payment Solutions Will Expand Healthcare Access Further
Key Takeaways Strategic diversification and regulatory alignment in healthcare and payments position Paysign to expand margins and strengthen its competitive advantage amid industry consolidation. Growth in digital payment demand, recurring high-margin healthcare programs, and adoption in gig payroll drive robust and resilient future revenue streams.
View narrative
US$9.10
FV
42.5% undervalued
intrinsic discount
21.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
6 days ago
author updated this narrative
Paysign
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Digital Payments And Healthcare Trends Will Drive Expansion
Key Takeaways New program wins and strengthening digital capabilities position Paysign for rapid revenue and margin growth, with pharma affordability poised to surpass legacy segments. Operational scale, automation, and compliance infrastructure create durable competitive advantages, enabling profitable expansion and increased revenue per client as digital adoption accelerates.
View narrative
US$9.50
FV
44.9% undervalued
intrinsic discount
25.16%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
27 days ago
author updated this narrative
Paysign
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
Plasma Decline And Fintech Risks Will Test Stability, Affordability Helps
Key Takeaways Overdependence on plasma and pharma reimbursement segments, combined with customer concentration, creates significant vulnerability to revenue and margin disruption. Rising compliance costs, competition from fintech innovation, and declining demand for prepaid cards threaten long-term growth and profitability.
View narrative
US$7.00
FV
25.3% undervalued
intrinsic discount
24.63%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 2 months ago
author updated this narrative
Your Valuation for
PAYS
PAYS
Paysign
Your Fair Value
US$
Current Price
US$5.23
36.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-13m
168m
2015
2018
2021
2024
2025
2027
2030
Revenue US$168.1m
Earnings US$16.6m
Advanced
Set Fair Value